Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Special Feature
You have accessRestricted Access

Prehypertension: Is It Relevant for Nephrologists?

Norman M. Kaplan
CJASN August 2009, 4 (8) 1381-1383; DOI: https://doi.org/10.2215/CJN.02340409
Norman M. Kaplan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Abstract

Prehypertension has been proposed as the diagnosis for the presence of blood pressures >120/80 mmHg but <140/90 mmHg. It covers more than 60 million people in the United States and nephrologists will increasingly be involved with them. This review describes its relevance to nephrologists.

Nephrologists will rarely deal with patients who have prehypertension (i.e., BP below hypertension [140/90 mmHg] but above ideal [120/80 mmHg]), which includes >60 million people in the United States (1). Because there are hardly enough nephrologists to care for the increasing number of patients with chronic kidney disease, why should they be concerned about patients who do not yet have hypertension?

The reasons include the following: First, multiple data show that people with prehypertension often have subclinical target organ damage, including nephropathy. Second, the families of patients with chronic kidney disease (CKD) harbor an increased prevalence of nephropathy, and they need early recognition. Third, if recognized, then it may be possible to reverse the usual progression into overt hypertension and thereby prevent patients from developing hypertension-related organ damage.

Evidence of Subclinical Target Organ Damage

During the past 10 yrs, a large body of evidence has shown the risks of prehypertensive levels of BP. Perhaps the most convincing are the data from the Prospective Studies Collaboration, which followed almost 1 million people with no previous vascular disease prospectively for a total of 12.7 million person-years in 61 observational studies (2) and examined the relationship between levels of BP and subsequent mortality. The data show a continuous increase in mortality from both stroke and ischemic heart disease from 115/75 mmHg, the lowest level with a large enough group that could be followed. In those with a 20-mmHg higher systolic BP or a 10-mmHg higher diastolic BP, mortality rates doubled; therefore, patients with BP of 135/85, well within the range of prehypertension, experienced a two-fold increase in death from cardiovascular diseases.

In addition to these mortality data, a number of studies of smaller populations have shown an increase in nonfatal target organ damage (3). For the sake of brevity, emphasis is placed on those that relate to the kidneys:

  • Left ventricular hypertrophy (4)

  • Coronary calcification (5)

  • Reduced coronary flow reserve (6)

  • Progression of coronary atherosclerosis (7)

  • Increases in ischemic coronary disease and stroke (8)

  • Poor cognitive function (9)

  • Retinal vascular changes (10)

  • Elevated serum uric acid (11)

Albuminuria in levels even below the level that defines microalbuminuria is predictive of both hypertension (12) and cardiovascular morbidity and mortality, independent of renal function, hypertension, or diabetes (13). Patients with prehypertension have an increased prevalence of microalbuminuria (14). In this study of almost 2700 patients, those with prehypertension had a prevalence of microalbuminuria of 4.9%, compared with a prevalence of 2.8% in those with normal BP. Similar associations have been reported from other populations (15). Of additional interest, serum uric acid, believed by some to be a major determinant of hypertension and atherosclerosis, is associated with microalbuminuria in individuals with prehypertension (16).

Predictors of Prehypertension

Because prehypertension is one step toward hypertension, the same factors are involved in the development of both. Obesity is foremost, with male gender and black race also involved (17). In addition, these factors are associated with more prehypertension: Diabetes, impaired glucose tolerance, the metabolic syndrome, dyslipidemia, and smoking (18).

Perhaps the main reason that nephrologists should consider prehypertension is their opportunity to identify many of those who are most likely to develop it: The families of their patients with CKD or ESRD. As shown in the Kidney Evaluation and Awareness Program in Sheffield (KEAPS) trial, relatives of patients with CKD were six times more likely to have microalbuminuria than nonrelatives (19). With the association of prehypertension with microalbuminuria, it is likely that many individuals with prehypertension would be identified with screening. That a relative has CKD should motivate those identified to change lifestyle or take medication to prevent developing CKD.

Value of Therapy

Both lifestyle changes (20) and drug therapy (21–23) have been shown at least temporarily to slow the progression of prehypertension into hypertension. The trials, up until now, have likely been too late to stop the progress, because, at least in the spontaneously hypertensive rat (24), antihypertensive therapy must be given much earlier in the lifespan to prevent the future development of hypertension.

Conclusions

Nephrologists have the closest relationship to hypertension than any other specialists. To be even more effective in the early recognition and, hopefully, the prevention of overt hypertension, they need to keep prehypertension in mind.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received April 8, 2009.
  • Accepted May 26, 2009.
  • Copyright © 2009 by the American Society of Nephrology

References

  1. 1.↵
    1. Elliott WJ,
    2. Black HR
    : Prehypertension. Nat Clin Pract Cardiovasc Med 4: 538–548, 2007
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lewington S,
    2. Clarke R,
    3. Qizilbash N,
    4. Peto R,
    5. Collins R
    , Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies [published erratum appears in Lancet 361: 1060, 2003]. Lancet 360: 1903–1913, 2002
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Carrington M
    : Prehypertension causes a mounting problem of harmful cardiovascular disease risk in young adults. J Hypertens 27: 214–215, 2009
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kokkinos P,
    2. Pittaras A,
    3. Narayan P,
    4. Faselis C,
    5. Singh S,
    6. Manolis A
    : Exercise capacity and blood pressure associations with left ventricular mass in prehypertensive individuals. Hypertension 49: 55–61, 2007
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Pletcher MJ,
    2. Bibbins-Domingo K,
    3. Lewis CE,
    4. Wei GS,
    5. Sidney S,
    6. Carr JJ,
    7. Vittinghoff E,
    8. McCulloch CE,
    9. Hulley SB
    : Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med 149: 91–99, 2008
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Erdogan D,
    2. Yildirim I,
    3. Ciftci O,
    4. Ozer I,
    5. Caliskan M,
    6. Gullu H,
    7. Muderrisoglu H
    : Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 115: 593–599, 2007
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Sipahi I,
    2. Tuzcu EM,
    3. Schoenhagen P,
    4. Wolski KE,
    5. Nicholls SJ,
    6. Balog C,
    7. Crowe TD,
    8. Nissen SE
    : Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 48: 833–838, 2006
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kshirsagar AV,
    2. Carpenter M,
    3. Bang H,
    4. Wyatt SB,
    5. Colindres RE
    : Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 119: 133–141, 2006
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Knecht S,
    2. Wersching H,
    3. Lohmann H,
    4. Bruchmann M,
    5. Duning T,
    6. Dziewas R,
    7. Berger K,
    8. Ringelstein EB
    : High-normal blood pressure is associated with poor cognitive performance. Hypertension 51: 663–668, 2008
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Nguyen TT,
    2. Wang JJ,
    3. Wong TY
    : Retinal vascular changes in pre-diabetes and prehypertension: New findings and their research and clinical implications. Diabetes Care 30: 2708–2715, 2007
    OpenUrlFREE Full Text
  11. 11.↵
    1. Syamala S,
    2. Li J,
    3. Shankar A
    : Association between serum uric acid and prehypertension among US adults. J Hypertens 25: 1583–1589, 2007
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Forman JP,
    2. Fisher ND,
    3. Schopick EL,
    4. Curhan GC
    : Higher levels of albuminuria within the normal range predict incident hypertension. J Am Soc Nephrol 19: 1983–1988, 2008
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Klausen K,
    2. Borch-Johnsen K,
    3. Feldt-Rasmussen B,
    4. Jensen G,
    5. Clausen P,
    6. Scharling H,
    7. Appleyard M,
    8. Jensen JS
    : Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110: 32–35, 2004
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Kim BJ,
    2. Lee HJ,
    3. Sung KC,
    4. Kim BS,
    5. Kang JH,
    6. Lee MH,
    7. Park JR
    : Comparison of microalbuminuria in 2 blood pressure categories of prehypertensive subjects. Circ J 71: 1283–1287, 2007
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hsu CC,
    2. Brancati FL,
    3. Astor BC,
    4. Kao WH,
    5. Steffes MW,
    6. Folsom AR,
    7. Coresh J
    : Blood pressure, atherosclerosis, and albuminuria in 10,113 participants in the atherosclerosis risk in communities study. J Hypertens 27: 397–409, 2009
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Lee JE,
    2. Kim YG,
    3. Choi YH,
    4. Huh W,
    5. Kim DJ,
    6. Oh HY
    : Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 47: 962–967, 2006
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Toprak A,
    2. Wang H,
    3. Chen W,
    4. Paul T,
    5. Ruan L,
    6. Srinivasan S,
    7. Berenson G
    : Prehypertension and black-white contrasts in cardiovascular risk in young adults: Bogalusa Heart Study. J Hypertens 27: 243–250, 2009
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Bo S,
    2. Gambino R,
    3. Gentile L,
    4. Pagano G,
    5. Rosato R,
    6. Saracco GM,
    7. Cassader M,
    8. Durazzo M,
    9. Cavallo-Perin P
    : High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: A population-based study. J Hypertens 27: 102–108, 2009
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Bello AK,
    2. Peters J,
    3. Wight J,
    4. De Zeeuw D,
    5. El Nahas M
    , European Kidney Institute: A population-based screening for microalbuminuria among relatives of CKD patients: The Kidney Evaluation and Awareness Program in Sheffield (KEAPS). Am J Kidney Dis 52: 434–443, 2008
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Bavikati VV,
    2. Sperling LS,
    3. Salmon RD,
    4. Faircloth GC,
    5. Gordon TL,
    6. Franklin BA,
    7. Gordon NF
    : Effect of comprehensive therapeutic lifestyle changes on prehypertension. Am J Cardiol 102: 1677–1680, 2008
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Julius S,
    2. Nesbitt SD,
    3. Egan BM,
    4. Weber MA,
    5. Michelson EL,
    6. Kaciroti N,
    7. Black HR,
    8. Grimm RH Jr.,
    9. Messerli FH,
    10. Oparil S,
    11. Schork MA
    , Trial of Preventing Hypertension (TROPHY) Study Investigators: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354: 1685–1697, 2006
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Skov K,
    2. Eiskjaer H,
    3. Hansen HE,
    4. Madsen JK,
    5. Kvist S,
    6. Mulvany MJ
    : Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 50: 89–95, 2007
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Luders S,
    2. Schrader J,
    3. Berger J,
    4. Unger T,
    5. Zidek W,
    6. Böhm M,
    7. Middeke M,
    8. Motz W,
    9. Lübcke C,
    10. Gansz A,
    11. Brokamp L,
    12. Schmieder RE,
    13. Trenkwalder P,
    14. Haller H,
    15. Dominiak P
    , PHARAO Study Group: The PHARAO study: Prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure—A prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487–1496, 2008
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Harrap SB,
    2. Van der Merwe WM,
    3. Griffin SA,
    4. Macpherson F,
    5. Lever AF
    : Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 16: 603–614, 1990
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 4, Issue 8
1 Aug 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Prehypertension: Is It Relevant for Nephrologists?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prehypertension: Is It Relevant for Nephrologists?
Norman M. Kaplan
CJASN Aug 2009, 4 (8) 1381-1383; DOI: 10.2215/CJN.02340409

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Prehypertension: Is It Relevant for Nephrologists?
Norman M. Kaplan
CJASN Aug 2009, 4 (8) 1381-1383; DOI: 10.2215/CJN.02340409
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Evidence of Subclinical Target Organ Damage
    • Predictors of Prehypertension
    • Value of Therapy
    • Conclusions
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Serious Illness Conversations in ESRD
  • Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP)
  • Climate Change and the Emergent Epidemic of CKD from Heat Stress in Rural Communities: The Case for Heat Stress Nephropathy
Show more Special Feature

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire